Department of Surgical Oncology and Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, 110000, China.
Department of Pathology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, 100005, China.
Clin Epigenetics. 2024 Sep 11;16(1):125. doi: 10.1186/s13148-024-01726-7.
Breast tumorigenesis is a complex and multistep process accompanied by both genetic and epigenetic dysregulation. In contrast to the extensive studies on DNA epigenetic modifications 5-hydroxymethylcytosine (5hmC) and 5-methylcytosine (5mC) in malignant breast tumors, their roles in the early phases of breast tumorigenesis remain ambiguous.
DNA 5hmC and 5mC exhibited a consistent and significant decrease from usual ductal hyperplasia to atypical ductal hyperplasia and subsequently to ductal carcinoma in situ (DCIS). However, 5hmC showed a modest increase in invasive ductal breast cancer compared to DCIS. Genomic analyses showed that the changes in 5hmC and 5mC levels occurred around the transcription start sites (TSSs), and the modification levels were strongly correlated with gene expression levels. Meanwhile, it was found that differentially hydroxymethylated regions (DhMRs) and differentially methylated regions (DMRs) were overlapped in the early phases and accompanied by the enrichment of active histone marks. In addition, TET2-related DNA demethylation was found to be involved in breast tumorigenesis, and four transcription factor binding sites (TFs: ESR1, FOXA1, GATA3, FOS) were enriched in TET2-related DhMRs/DMRs. Intriguingly, we also identified a certain number of common DhMRs between tumor samples and cell-free DNA (cfDNA).
Our study reveals that dynamic changes in DNA 5hmC and 5mC play a vital role in propelling breast tumorigenesis. Both TFs and active histone marks are involved in TET2-related DNA demethylation. Concurrent changes in 5hmC signals in primary breast tumors and cfDNA may play a promising role in breast cancer screening.
乳腺肿瘤发生是一个复杂的多步骤过程,伴随着遗传和表观遗传失调。与恶性乳腺肿瘤中 DNA 表观遗传修饰 5-羟甲基胞嘧啶(5hmC)和 5-甲基胞嘧啶(5mC)的广泛研究相比,它们在乳腺肿瘤发生的早期阶段的作用仍不明确。
DNA 5hmC 和 5mC 从普通导管增生到非典型导管增生,再到导管原位癌(DCIS)呈一致且显著下降。然而,与 DCIS 相比,浸润性导管乳腺癌中 5hmC 略有增加。基因组分析表明,5hmC 和 5mC 水平的变化发生在转录起始位点(TSS)周围,修饰水平与基因表达水平强烈相关。同时,发现差异羟甲基化区域(DhMRs)和差异甲基化区域(DMRs)在早期阶段重叠,并伴有活性组蛋白标记的富集。此外,发现 TET2 相关的 DNA 去甲基化参与乳腺肿瘤发生,并且在 TET2 相关 DhMRs/DMRs 中富集了四个转录因子结合位点(TFs:ESR1、FOXA1、GATA3、FOS)。有趣的是,我们还在肿瘤样本和无细胞 DNA(cfDNA)之间鉴定了一定数量的共同 DhMRs。
本研究揭示了 DNA 5hmC 和 5mC 的动态变化在推动乳腺肿瘤发生中起着至关重要的作用。TFs 和活性组蛋白标记均参与 TET2 相关的 DNA 去甲基化。原发性乳腺癌和 cfDNA 中 5hmC 信号的同时变化可能在乳腺癌筛查中发挥有前景的作用。